Overview

* AxoGen ( AXGN ) Q2 revenue rises 18.3% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus, reflecting improved operational performance

* Co raises full-year revenue growth guidance to at least 17%

Outlook

* AxoGen ( AXGN ) raises full-year revenue guidance to at least 17% growth

* Company expects 2025 revenue of $219 mln

* AxoGen ( AXGN ) anticipates gross margin of 73% to 75% for 2025

* Company expects net cash flow positive for full year

Result Drivers

* BROAD-BASED GROWTH - AxoGen ( AXGN ) reports double-digit revenue growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

* EXPANDED COVERAGE - Co adds 10 mln new covered lives for nerve repair solutions, increasing total coverage to over 55% among commercial payers

* GROSS MARGIN IMPROVEMENT - Gross margin increased to 74.2%, reflecting improved operational efficiency

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $56.70 $52.70

Revenue mln mln (8

Analysts

)

Q2 Beat $0.12 $0.06 (6

Adjusted Analysts

EPS )

Q2 $5.70

Adjusted mln

Net

Income

Q2 Net $600,000

Income

Q2 $9.30

Adjusted mln

EBITDA

Q2 Gross 74.2%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for AxoGen Inc ( AXGN ) is $24.00, about 47.7% above its August 4 closing price of $12.55

* The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 46 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)